Last reviewed · How we verify
Perindopril plus Hydrochlorothiazide
Perindopril inhibits angiotensin-converting enzyme (ACE) to reduce vasoconstriction and aldosterone secretion, while hydrochlorothiazide promotes sodium and water excretion to lower blood volume, together reducing blood pressure.
Perindopril inhibits angiotensin-converting enzyme (ACE) to reduce vasoconstriction and aldosterone secretion, while hydrochlorothiazide promotes sodium and water excretion to lower blood volume, together reducing blood pressure. Used for Hypertension, Heart failure (perindopril component).
At a glance
| Generic name | Perindopril plus Hydrochlorothiazide |
|---|---|
| Sponsor | University of Abuja |
| Drug class | ACE inhibitor plus thiazide diuretic combination |
| Target | Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter in the distal convoluted tubule |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Perindopril blocks ACE, preventing conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that increases urinary sodium and water excretion, decreasing intravascular volume and blood pressure. The combination provides complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
- Heart failure (perindopril component)
Common side effects
- Cough
- Dizziness
- Hyperuricemia
- Hypokalemia
- Hyperglycemia
- Fatigue
- Angioedema
Key clinical trials
- ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension (PHASE2)
- Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Fimasartan in the Senior Subjects (PHASE3)
- Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women. (PHASE4)
- RAS Peptide Profiles in Patients With Arterial Hypertension
- Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perindopril plus Hydrochlorothiazide CI brief — competitive landscape report
- Perindopril plus Hydrochlorothiazide updates RSS · CI watch RSS
- University of Abuja portfolio CI